Serum and synovial matrix metalloproteinase-3 as markers of disease activity in early rheumatoid arthritis
Joint Authors
Fawzi, Rasha M.
Abd al-Hamid, Yasir A.
al-Bihisi, Muna M.
Abu al-Majid, Rasha F.
Source
Egyptian Rheumatology and Rehabilitation
Issue
Vol. 43, Issue 4 (31 Dec. 2016), pp.178-183, 6 p.
Publisher
The Egyptian Society for Rheumatology and Rehabilitation
Publication Date
2016-12-31
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Background Matrix metalloprotein ase-3 (MMP-3) is one of the MMPs produced in rheumatoid arthritis (RA) joints.
Aim The aim of this study was to evaluate serum and synovial fluid (SF) MMP-3 as markers of disease activity in early RA.
Patients and methods Thirty early RA patients together with age-matched and sex-matched 12 primary knee osteoarthritis patients and 12 apparently healthy individuals as control groups were enrolled in this study.
MMP-3 was measured in serum and SF samples using enzyme-linked immunosorbent assay.
Assessment of disease activity in RA patients was carried out using disease activity score-28 (DAS-28), and radiographs of the hands, wrists, and forefeet were obtained and evaluated according to Larsen score.
Results As regards mean serum levels of MMP-3, there was a statistically significant elevation in RA patients compared with the control groups (P<0.001).
Moreover, the mean SF levels of MMP-3 in RA patients were statistically significantly higher than that in osteoarthritis patients (P<0.001).
In RA patients, there was a statistically significant difference (P<0.001) between mean serum and SF levels, being higher in the SF.
There was a statistically significant positive correlation (P<0.05) between serum MMP-3 with disease duration, DAS-28, and Larsen score.
As regards mean SF MMP-3 levels, there was a high statistically significant positive correlation (P<0.001) with DAS-28 and a statistically significant positive correlation (P<0.05) with Larsen score.
Conclusion Elevated serum and synovial MMP-3 levels reflect disease activity in RA patients; thus, it could be used as a useful marker for disease activity.
The cross-sectional design of our study did not allow us to produce conclusions with respect to disease course and prognosis.
Thus, we recommend further studies on large numbers of patients and serial measurements of MMP-3 to determine the rate of disease progression.
American Psychological Association (APA)
Fawzi, Rasha M.& Abd al-Hamid, Yasir A.& al-Bihisi, Muna M.& Abu al-Majid, Rasha F.. 2016. Serum and synovial matrix metalloproteinase-3 as markers of disease activity in early rheumatoid arthritis. Egyptian Rheumatology and Rehabilitation،Vol. 43, no. 4, pp.178-183.
https://search.emarefa.net/detail/BIM-753307
Modern Language Association (MLA)
Fawzi, Rasha M.…[et al.]. Serum and synovial matrix metalloproteinase-3 as markers of disease activity in early rheumatoid arthritis. Egyptian Rheumatology and Rehabilitation Vol. 43, no. 4 (Oct. / Dec. 2016), pp.178-183.
https://search.emarefa.net/detail/BIM-753307
American Medical Association (AMA)
Fawzi, Rasha M.& Abd al-Hamid, Yasir A.& al-Bihisi, Muna M.& Abu al-Majid, Rasha F.. Serum and synovial matrix metalloproteinase-3 as markers of disease activity in early rheumatoid arthritis. Egyptian Rheumatology and Rehabilitation. 2016. Vol. 43, no. 4, pp.178-183.
https://search.emarefa.net/detail/BIM-753307
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 182-183
Record ID
BIM-753307